Table 1.

Patient demographics and disease characteristics at baseline by treatment arm in patients with positive anti-HBc serology (analysis population, n = 326)

CharacteristicG-Chemo (n = 155)R-Chemo (n = 171)
Median age, y (range)61 (25-81)59 (19-83)
Female, n (%)60 (38.7)81 (47.4)
Race, n (%)
 White49 (31.6)64 (37.4)
 Black3 (1.9)0
 Asian103 (66.5)105 (61.4)
 Other02 (1.2)
Region, n (%)
 East Asia*86 (55.5)89 (52.0)
 Europe48 (31.0)57 (33.3)
 Other21 (13.5)25 (14.6)
Lymphoma type, n (%)
 DLBCL (GOYA)121 (78.1)114 (66.7)
 FL (GALLIUM)29 (18.7)53 (31.0)
 MZL (GALLIUM)5 (3.2)4 (2.3)
HBV serology, n (%)
 Anti-HBc+, anti-HBs+94 (60.6)113 (66.1)
 Anti-HBc+, anti-HBs-57 (36.8)52 (30.4)
 Missing anti-HBs4 (2.6)6 (3.5)
HBV DNA <29 IU/mL at baseline, n (%)
 Not detectable143 (92.3)157 (91.8)
 Detectable, but not quantifiable7 (4.5)4 (2.3)
 Missing5 (3.2)10 (5.8)
ECOG performance status, n (%)
 076 (49.0)81 (47.4)
 168 (43.9)69 (40.4)
 211 (7.1)21 (12.3)
IPI risk category (GOYA), n (%)n = 121n = 114
 High20 (16.5)18 (15.8)
 High-intermediate41 (33.9)31 (27.2)
 Low-intermediate38 (31.4)42 (36.8)
 Low22 (18.2)23 (20.2)
FLIPI-1 risk category (GALLIUM, FL), n (%)n = 29n = 53
 High11 (37.9)21 (39.6)
 Intermediate10 (34.5)19 (35.8)
 Low8 (27.6)13 (24.5)
IPI risk category (GALLIUM, non-FL), n (%)n = 5n = 4
 High1 (20.0)0
 High-intermediate2 (40.0)2 (50.0)
 Low-intermediate1 (20.0)1 (25.0)
 Low1 (20.0)1 (25.0)
Prophylactic NAT, n (%)40 (25.8)54 (31.6)
 Lamivudine33 (21.3)46 (26.9)
 Entecavir7 (4.5)8 (4.7)
Treatment, n (%)
 CHOP141 (91.0)§148 (86.5)
 Benda13 (8.4)19 (11.1)
 CVP1 (0.6)4 (2.3)
  • Benda, bendamustine; Chemo, chemotherapy; CVP, cyclophosphamide, vincristine, and prednisone; ECOG, Eastern Cooperative Oncology Group; FLIPI, Follicular Lymphoma International Prognostic Index; G, obinutuzumab; IPI, International Prognostic Index; MZL, marginal zone lymphoma; R, rituximab.

  • * East Asia includes China, Japan, South Korea, and Taiwan.

  • Europe includes Belgium, Czech Republic, Germany, Hungary, Italy, Russia, Spain, Switzerland, and the United Kingdom.

  • Other includes Australia, Canada, and Thailand.

  • § G-CHOP: GOYA, n = 121; GALLIUM, n = 20.

  • R-CHOP: GOYA, n = 114; GALLIUM, n = 34.